BACKGROUND: Lymphotropic Polyomavirus (LPV) was isolated from a B-lymphoblastoid cell line of an African green monkey. This virus shares some characteristics with human polyomaviruses, but it is antigenically distinct from BK Virus (BKV) and JC Virus (JCV). Seroepidemiological studies revealed that human sera react in the presence of LPV antigens, and, recently, the viral genome was amplified in the peripheral blood from patients affected with HIV-related leukoencephalopathies. OBJECTIVES: The aims of the study were to investigate and compare the presence of LPV DNA with that of JCV and BKV in different biological samples and patient groups. STUDY DESIGN: LPV, JCV and BKV DNA were searched and quantified in peripheral blood and CSF from HIV+ patients and in peripheral blood from healthy subjects. RESULTS: The LPV genome was detected in peripheral blood of both HIV+ patients and healthy subjects, with a prevalence of 7.2% and 4.7% respectively, but not in CSF. However, its presence was less frequent than that of JCV and BKV. CONCLUSIONS: The amplification of LPV genome from human peripheral blood confirms the fact that LPV can infect the human population. LPV DNA was amplified from patients affected with HIV-related leukoencephalopathies but also from HIV patients without neurological disorders and from healthy subjects. Therefore, the results do not support the hypothesis of an association between LPV infection and any neurological disease. However, given their high similarity, it is possible that LPV, as well as BKV and JCV, could establish latency in humans and cause disease only in rare circumstances.
BACKGROUND:Lymphotropic Polyomavirus (LPV) was isolated from a B-lymphoblastoid cell line of an African green monkey. This virus shares some characteristics with humanpolyomaviruses, but it is antigenically distinct from BK Virus (BKV) and JC Virus (JCV). Seroepidemiological studies revealed that human sera react in the presence of LPV antigens, and, recently, the viral genome was amplified in the peripheral blood from patients affected with HIV-related leukoencephalopathies. OBJECTIVES: The aims of the study were to investigate and compare the presence of LPV DNA with that of JCV and BKV in different biological samples and patient groups. STUDY DESIGN:LPV, JCV and BKV DNA were searched and quantified in peripheral blood and CSF from HIV+ patients and in peripheral blood from healthy subjects. RESULTS: The LPV genome was detected in peripheral blood of both HIV+ patients and healthy subjects, with a prevalence of 7.2% and 4.7% respectively, but not in CSF. However, its presence was less frequent than that of JCV and BKV. CONCLUSIONS: The amplification of LPV genome from human peripheral blood confirms the fact that LPV can infect the human population. LPV DNA was amplified from patients affected with HIV-related leukoencephalopathies but also from HIV patients without neurological disorders and from healthy subjects. Therefore, the results do not support the hypothesis of an association between LPV infection and any neurological disease. However, given their high similarity, it is possible that LPV, as well as BKV and JCV, could establish latency in humans and cause disease only in rare circumstances.
Authors: Y M Lo; M S Tein; T K Lau; C J Haines; T N Leung; P M Poon; J S Wainscoat; P J Johnson; A M Chang; N M Hjelm Journal: Am J Hum Genet Date: 1998-04 Impact factor: 11.025
Authors: P Ferrante; R Caldarelli-Stefano; E Omodeo-Zorini; A E Cagni; L Cocchi; F Suter; R Maserati Journal: J Med Virol Date: 1997-07 Impact factor: 2.327
Authors: Wendy A Knowles; Pam Pipkin; Nick Andrews; Andrew Vyse; Philip Minor; David W G Brown; Elizabeth Miller Journal: J Med Virol Date: 2003-09 Impact factor: 2.327
Authors: Virginie Sauvage; Vincent Foulongne; Justine Cheval; Meriadeg Ar Gouilh; Kevin Pariente; Olivier Dereure; Jean Claude Manuguerra; Jennifer Richardson; Marc Lecuit; Ana Burguière; Valérie Caro; Marc Eloit Journal: Emerg Infect Dis Date: 2011-08 Impact factor: 6.883
Authors: Adrienne L McNees; Lindsay J Harrigal; Aoife Kelly; Charles G Minard; Connie Wong; Janet S Butel Journal: PLoS One Date: 2018-02-12 Impact factor: 3.240
Authors: Sergio Kamminga; Els van der Meijden; Caroline de Brouwer; Mariet Feltkamp; Hans Zaaijer Journal: Transfusion Date: 2019-10-21 Impact factor: 3.157
Authors: Annika Antonsson; Seweryn Bialasiewicz; Rebecca J Rockett; Kevin Jacob; Ian C Bennett; Theo P Sloots Journal: PLoS One Date: 2012-08-15 Impact factor: 3.240